India expects first foreign-made COVID-19 doses through COVAX by August- sources

NEW DELHI, July 7 (Reuters) - India expects to receive foreign-made COVID-19 vaccine doses through the COVAX global vaccine-sharing programme for the first time, with3-4 million doses of Pfizer (PFE.N) and Moderna (MRNA.O) shots potentially arriving by August, two sources said on Wednesday.

India, the world's biggest producer of vaccines, was initially the main source of COVID-19 shots for the COVAX programme, but halted its exports in April after a massive wave of COVID-19 infections, having sold or donated 66 million shots.

COVAX could ship the U.S.-made doses to India as early as this month, one of the sources aware of the discussions told Reuters. Both sources declined to be named as the discussions are private.

A spokesperson for GAVI, a vaccine alliance which runs COVAX alongside the World Health Organization, said talks were underway "to ensure U.S.-donated doses through COVAX can reach India quickly, and we look forward to being able to deliver to India once all legal requirements are concluded".

In June, U.S. President Joe Biden had announced the United States would donate 500 million doses of the Pfizer COVID-19 vaccine to the world's poorest countries. read more

Pfizer and Moderna did not immediately reply to e-mails seeking comment. India's foreign ministry also did not reply to queries.

India has so far administered 359.6 million vaccine doses - the most in the world after China - giving at least one dose to 31% of its estimated adult population of 944 million.

India mainly relies on a version of the AstraZeneca (AZN.L) vaccine produced under license, as well as a domestically developed shot, Covaxin. Itwould need to administer 10 million doses a day to achieve its aim of immunising all adults by December; it administered about 4 million doses a day last week.

India has also been courting Johnson & Johnson (JNJ.N) for vaccine supplies. J&J has already signed a manufacturing agreement with India's Biological E. Ltd, though production has yet to start. A J&J spokesperson in India said the company was looking to expedite supplies.

"We are exploring how best to accelerate our ability to deliver our vaccine to the people of India through our global COVID-19 vaccine supply network, including our partnership with Biological E. Limited," the spokesperson saidin an e-mail.

Reporting by Rupam Jain in Mumbai and Neha Arora in New Delhi; Additional reporting by Krishna N. Das; Editing by Gareth Jones

Our Standards: The Thomson Reuters Trust Principles.